LDK378
CLDK378X2102
Phase 1 small_molecule completed
Quick answer
LDK378 for Anaplastic Lymphoma Kinase (ALK) is a Phase 1 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Anaplastic Lymphoma Kinase (ALK)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed